MicroRNA-21 silencing enhances the cytotoxic effect of the antiangiogenic drug sunitinib in glioblastoma
Open accessAbstract
Highly malignant glioblastoma (GBM) is characterized by high genetic heterogeneity and infiltrative brain invasion patterns, and aberrant miRNA expression has been associated with hallmark malignant properties of GBM. The lack of effective GBM treatment options prompted us to investigate whether miRNAs would constitute promising therapeutic targets toward the generation of a gene therapy approach with clinical significance for this disease. Here, we show that microRNA-21 (miR-21) is upregulated and microRNA-128 (miR-128) is downregulated in mouse and human GBM samples, a finding that is corroborated by analysis of a large set of human GBM data from The Cancer Genome Atlas. Moreover, we demonstrate that oligonucleotide-mediated miR-21 silencing in U87 human GBM cells resulted in increased levels of the tumor suppressors PTEN and PDCD4, caspase 3/7 activation and decreased tumor cell proliferation. Cell exposure to pifithrin, an inhibitor of p53 transcriptional activity, reduced the caspase activity associated with decreased miR-21 expression. Finally, we demonstrate for the first time that miR-21 silencing enhances the antitumoral effect of the tyrosine kinase inhibitor sunitinib, whereas no therapeutic benefit is observed when coupling miR-21 silencing with the first-line drug temozolomide. Overall, our results provide evidence that miR-21 is uniformly overexpressed in GBM and constitutes a highly promising target for multimodal therapeutic approaches toward GBM.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Suppressing miR-21 enhanced the therapeutic effects of antiangiogenic drug sunitinib in glioblastoma.
“Suppressing miR-21 also enhanced the therapeutic effects of antiangiogenic drug, sunitinib, in glioblastoma (55).”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · see citing works
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714 · see citing works
A new mathematical model for relative quantification in real-time RT-PCR
Pfaffl, M. W. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.9.e45 · Cited by 34,610 · see citing works
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807 · see citing works
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735 · see citing works
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., TAPHOORN, M. J. B., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Bélanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,667 · see citing works
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575 · see citing works
Oncomirs — microRNAs with a role in cancer
Esquela‐Kerscher, A., & Slack, F. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1840 · Cited by 7,038 · see citing works
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · see citing works
Mammalian microRNAs predominantly act to decrease target mRNA levels
Guo, H., Ingolia, N. T., Weissman, J. S., & Bartel, D. P. (2010) · Nature · doi:10.1038/nature09267 · Cited by 3,886 · see citing works
O'Brien, J., Wilson, I., Orton, T., & Pognan, F. (2000) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2000.01606.x · Cited by 3,446 · see citing works
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773 · see citing works
MicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557 · see citing works
A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia
Calin, G. A., Ferracin, M., Cimmino, A., Leva, G. D., Shimizu, M., Wojcik, S. E., Iorio, M. V., Visone, R., Sever, N. İ., Fabbri, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050995 · Cited by 2,403 · see citing works
Asangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · see citing works
Genetic Pathways to Primary and Secondary Glioblastoma
Ohgaki, H., & Kleihues, P. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2007.070011 · Cited by 1,487 · see citing works
Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs
Bartel, D. P., & Chen, C. (2004) · Nature Reviews Genetics · doi:10.1038/nrg1328 · Cited by 1,417 · see citing works
Inflammation meets cancer, with NF-κB as the matchmaker
Ben‐Neriah, Y., & Karin, M. (2011) · Nature Immunology · doi:10.1038/ni.2060 · Cited by 1,378 · see citing works
Banker, G. A., & Goslin, K. (1998) · Cited by 1,290 · see citing works
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096 · see citing works
MicroRNA-21 Targets the Tumor Suppressor Gene Tropomyosin 1 (TPM1)
Zhu, S., Si, M.-L., Wu, H., & Mo, Y.-Y. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611393200 · Cited by 1,090 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · see citing works
MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00479-08 · Cited by 888 · see citing works
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831 · see citing works
Silber, J., Lim, D. A., Petritsch, C., Persson, A. I., Maunakea, A. K., Yu, M., Vandenberg, S. R., Ginzinger, D. G., James, C. D., Costello, J. F., et al. (2008) · BMC Medicine · doi:10.1186/1741-7015-6-14 · Cited by 765 · see citing works
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711 · see citing works
MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
Papagiannakopoulos, T., Shapiro, A., & Kosik, K. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1305 · Cited by 705 · cited 2× · see citing works
“MiR-21 has also been shown to target multiple components of important apoptosis-related pathways, including p53, TGF-b and mitochondrial apoptosis (29).”
BackgroundGodlewski, J. A., Nowicki, M. O., Bronisz, A., Williams, S. P., Otsuki, A., Nuovo, G. J., Ray‐Chaudhury, A., Newton, H. B., Chiocca, E. A., & Lawler, S. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2629 · Cited by 702 · see citing works
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494 · see citing works
miR-21 as a key regulator of oncogenic processes
Selçuklu, S. D., Donoghue, M. T. A., & Spillane, C. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370918 · Cited by 446 · see citing works
Corsten, M. F., Miranda, R., Kasmieh, R., Krichevsky, A. M., Weissleder, R., & Shah, K. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1045 · Cited by 406 · see citing works
Zhou, X., Ren, Y., Moore, L. M., Mei, M., You, Y., Xu, P., Wang, B., Wang, G., Jia, Z., Pu, P., et al. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2009.126 · Cited by 358 · see citing works
Cardoso, A. L., Guedes, J. R., Pereira de Almeida, L., & Pedroso de Lima, M. C. (2012) · Immunology · doi:10.1111/j.1365-2567.2011.03514.x · Cited by 336 · see citing works
Self-citationThe p53 family in differentiation and tumorigenesis
Stiewe, T. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2072 · Cited by 306 · see citing works
miRNA in situ hybridization in formaldehyde and EDC–fixed tissues
Pena, J., Sohn-Lee, C., Rouhanifard, S. H., Ludwig, J., Hafner, M., Mihailovic, A., Lim, C., Holoch, D., Berninger, P., Zavolan, M., et al. (2009) · Nature Methods · doi:10.1038/nmeth.1294 · Cited by 292 · see citing works
(1998) · The MIT Press eBooks · doi:10.7551/mitpress/4913.001.0001 · Cited by 272 · see citing works
miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors
Conti, A., Aguennouz, M., Torre, D. L., Tomasello, C., Cardali, S. M., Angileri, F. F., Maio, F., Cama, A., Germanò, A., Vita, G., et al. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9797-4 · Cited by 229 · see citing works
de Almeida, L. P., Ross, C. A., Zala, D., Aebischer, P., & Déglon, N. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03473.2002 · Cited by 226 · see citing works
MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G
Chen, Y., Liu, W., Chao, T., Zhang, Y., Yan, X., Gong, Y., Qiang, B., Yuan, J., Sun, M., & Peng, X. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.06.034 · Cited by 217 · see citing works
Prados, M. D., Lamborn, K. R., Chang, S. M., Burton, E. M., Butowski, N. A., Malec, M. K., Kapadia, A., Rabbitt, J. E., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 217 · see citing works
Ren, Y., Zhou, X., Mei, M., Yuan, X.-B., Han, L., Wang, G., Jia, Z.-F., Xu, P., Pu, P., & Kang, C. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-27 · Cited by 216 · see citing works
Heinzelmann, J., Henning, B., Sanjmyatav, J., Posorski, N., Steiner, T., Wunderlich, H., Gajda, M. R., & Junker, K. (2011) · World Journal of Urology · doi:10.1007/s00345-010-0633-4 · Cited by 198 · see citing works
The microRNA network and tumor metastasis
Zhang, H., Li, Y., & Lai, M. (2009) · Oncogene · doi:10.1038/onc.2009.406 · Cited by 185 · see citing works
Yang, H.-S., Jansen, A. P., Nair, R., Shibahara, K., Verma, A. K., Cmarik, J. L., & Colburn, N. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204137 · Cited by 185 · see citing works
Downregulation of Pdcd4 by mir-21 facilitates glioblastoma proliferation in vivo
Gaur, A. B., Holbeck, S. L., Colburn, N. H., & Israel, M. A. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor033 · Cited by 180 · cited 1× · see citing works
“Here, and in accordance with previous studies (42,44), we provide evidence that oligonucleotide-mediated miR-21 silencing increases the expression levels of the Figure 7.”
Resultp53 and NF‐κB: different strategies for responding to stress lead to a functional antagonism
Ak, P., & Levine, A. J. (2010) · The FASEB Journal · doi:10.1096/fj.10-160549 · Cited by 178 · see citing works
Ren, Y. T., Kang, C., Yuan, X.-B., Zhou, X., Xu, P., Han, L., Wang, G. X., Jia, Z., Zhong, Y., Yu, S., et al. (2010) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856209x415828 · Cited by 175 · see citing works
Lei, L., Sonabend, A. M., Guarnieri, P., Soderquist, C. R., Ludwig, T. E., Rosenfeld, S. A., Bruce, J. N., & Canoll, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020041 · Cited by 145 · see citing works
Self-citationPhase II study of sunitinib malate in patients with recurrent high-grade glioma
Neyns, B., Sadones, J., Chaskis, C., Dujardin, M., Everaert, H., Lv, S., Duerinck, J., Tynninen, O., Nupponen, N. N., Michotte, A., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0402-7 · Cited by 138 · see citing works
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1
Göke, R., Barth, P. J., Schmidt, A., Samans, B., & Lankat–Buttgereit, B. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00025.2004 · Cited by 135 · see citing works
Neuropeptide Y Modulation of Interleukin-1β (IL-1β)-induced Nitric Oxide Production in Microglia
Ferreira, R., Xapelli, S., Santos, T., Silva, A. P., Cristóvão, A. J., Cortes, L., & Malva, J. O. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.164020 · Cited by 122 · see citing works
Advances in the Treatment of Malignant Gliomas
Khasraw, M., & Lassman, A. B. (2010) · Current Oncology Reports · doi:10.1007/s11912-009-0077-4 · Cited by 119 · see citing works
Emerging functions of microRNAs in glioblastoma
Lawler, S. E., & Chiocca, E. A. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9843-2 · Cited by 108 · see citing works
Murphy, P. J. M., Galigniana, M. D., Morishima, Y., Harrell, J. M., Kwok, R. P. S., Ljungman, M. E., & Pratt, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403539200 · Cited by 108 · see citing works
Alves, S., Nascimento-Ferreira, I., Dufour, N., Hässig, R., Aurégan, G., Nóbrega, C., Brouillet, E., Hantraye, P., de Lima, M. C. P., Déglon, N., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq111 · Cited by 106 · see citing works
Self-citationFrequent loss of PDCD4 expression in human glioma: Possible role in the tumorigenesis of glioma
Gao, F., Zhang, P., Zhou, C., Li, J., Wang, Q., Zhu, F., Ma, C., Sun, W., & Zhang, L. (2007) · Oncology Reports · doi:10.3892/or.17.1.123 · Cited by 100 · see citing works
p53 and NF-κB Crosstalk: IKKα Tips the Balance
Tergaonkar, V., & Perkins, N. D. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.04.006 · Cited by 95 · see citing works
Lee, H.-J., Choi, H. J., Kang, C. S., Lee, H. J., Lee, W. S., & Park, C. S. (2012) · Modern Pathology · doi:10.1038/modpathol.2012.111 · Cited by 87 · see citing works
PI3Kinase signaling in glioblastoma
Lino, M. M., & Merlo, A. U. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0442-z · Cited by 80 · see citing works
Lena, A., Rechichi, M., Salvetti, A., Bartoli, B., Vecchio, D., Scarcelli, V., Amoroso, R., Benvenuti, L., Gagliardi, R., Gremigni, V., et al. (2009) · Journal of Translational Medicine · doi:10.1186/1479-5876-7-13 · Cited by 59 · see citing works
The p53-inhibitor Pifithrin-α inhibits Firefly Luciferase activity in vivo and in vitro
Rocha, S., Campbell, K. J., Roche, K. C., & Perkins, N. D. (2003) · BMC Molecular Biology · doi:10.1186/1471-2199-4-9 · Cited by 55 · see citing works
P53 activation plays a crucial role in silibinin induced ROS generation via PUMA and JNK
Fan, S., Qi, M., Yu, Y., Li, L., Yao, G., Tashiro, S., Onodera, S., & Ikejima, T. (2012) · Free Radical Research · doi:10.3109/10715762.2012.655244 · Cited by 51 · see citing works
Trabulo, S. M. D., Resina, S., Simões, S., Lebleu, B., & de Lima, M. C. P. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.021 · Cited by 38 · see citing works
Effects of p53 inhibitor on survival and death of cells subjected to oxidative stress.
Strosznajder, R. P., Jęśko, H. M., Banasik, M., & Tanaka, S. (2005) · PubMed · Cited by 24 · see citing works
Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas
Morris, P. G., & Abrey, L. E. (2010) · Targeted Oncology · doi:10.1007/s11523-010-0160-7 · Cited by 22 · see citing works
Hank, N. C., Shapiro, J. R., & Scheck, A. C. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-2 · Cited by 6 · see citing works
Kim, S., Han, J., Lee, S. K., Hur, S. M., Koo, M., Cho, D. H., Bae, S. Y., Choi, M.-Y., Shin, I., Yang, J.-H., et al. (2010) · Pharmacology · doi:10.1159/000321327 · Cited by 6 · see citing works
Flagged first, then by citations
2 of the 69 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 541 · see citing works
Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review
Singh, N. C., Miner, A., Hennis, L., & Mittal, S. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.79 · Cited by 408 · see citing works
Xu, Z., Chen, Y., Ma, L., Chen, Y., Liu, J., Guo, Y., Yu, T., Zhang, L., Zhu, L., & Shu, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.01.046 · Cited by 325 · see citing works
Gambari, R., Brognara, E., Spandidos, D. A., & Fabbri, E. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3503 · Cited by 261 · see citing works
MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics
Shea, A. A., Harish, V., Afzal, Z., Chijioke, J., Kedir, H., Dusmatova, S., Roy, A., Ramalinga, M., Harris, B. T., Blancato, J. K., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.775 · Cited by 207 · see citing works
Costa, P. M., Cardoso, A. L., Custódia, C., Cunha, P. P., de Almeida, L. P., & de Lima, M. C. P. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.002 · Cited by 189 · see citing works
Self-citationFu, C., Li, D., Zhang, X., Liu, N., Chi, G., & Jin, X. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-0649-9 · Cited by 174 · see citing works
RetractedCabrini, G., Fabbri, E., Nigro, C. L., Dechecchi, M. C., & Gambari, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3026 · Cited by 141 · see citing works
Glioblastoma: Molecular Pathways, Stem Cells and Therapeutic Targets
Jhanwar‐Uniyal, M., LaBagnara, M., Friedman, M., Kwasnicki, A. M., & Murali, R. (2015) · Cancers · doi:10.3390/cancers7020538 · Cited by 126 · see citing works
Monfared, H., Jahangard, Y., Nikkhah, M., Mirnajafi-Zadeh, J., & Mowla, S. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00782 · Cited by 123 · see citing works
“Suppressing miR-21 also enhanced the therapeutic effects of antiangiogenic drug, sunitinib, in glioblastoma (55).”
BackgroundCosta, P. M., Cardoso, A. L., Mendonça, L. S., Serani, A., Custódia, C., Conceição, M., Simões, S., Moreira, J. N., de Almeida, L. P., & de Lima, M. C. P. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.30 · Cited by 120 · see citing works
Self-citationMicroRNAs in glioblastoma pathogenesis and therapy: A comprehensive review
Ahir, B. K., Ozer, H., Engelhard, H. H., & Lakka, S. S. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.10.003 · Cited by 118 · see citing works
The Roles of miRNA in Glioblastoma Tumor Cell Communication: Diplomatic and Aggressive Negotiations
Buruiană, A., Florian, I. Ş., Florian, I. A., Timiș, T. L., Mihu, C. M., Miclăuș, M., Oșan, S., Hrapșa, I., Cataniciu, R. C., Farcas, M. F., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061950 · Cited by 118 · see citing works
The Emerging Roles of Exosomes as EMT Regulators in Cancer
Kim, H., Lee, S.-M., Shin, E., Seong, K., Jin, Y., Youn, H., & Youn, B. (2020) · Cells · doi:10.3390/cells9040861 · Cited by 109 · see citing works
Gao, S., Tian, H., Guo, Y., Li, Y., Guo, Z., Zhu, X., & Chen, X. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.07.020 · Cited by 118 · see citing works
MicroRNA-21: a therapeutic target for reversing drug resistance in cancer
Hong, L., Han, Y., Zhang, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.819853 · Cited by 103 · see citing works
Moreira, R., Nóbrega, C., de Almeida, L. P., & Mendonça, L. S. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02511-7 · Cited by 91 · see citing works
Self-citationEnhanced Inhibition of Tumorigenesis Using Combinations of miRNA-Targeted Therapeutics
Miroshnichenko, S. K., & Patutina, O. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00488 · Cited by 81 · see citing works
Involvement of MicroRNA in Microglia-Mediated Immune Response
Guedes, J. R., Cardoso, A. L., & de Lima, M. C. P. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/186872 · Cited by 79 · see citing works
Self-citationmiRNAs: micro-managers of anticancer combination therapies
B, J. R. V. B., Giovannetti, E., Poel, D., Nowak-Sliwinska, P. M., & Griffioen, A. W. (2017) · Angiogenesis · doi:10.1007/s10456-017-9545-x · Cited by 74 · see citing works
Lei, B., Huang, Y., Zhou, Z., Zhao, Y., Thapa, A. J., Li, W., Cai, W., & Deng, Y. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27966 · Cited by 73 · see citing works
miRNA Multiplayers in glioma. From bench to bedside
Rolle, K. (2015) · Acta Biochimica Polonica · doi:10.18388/abp.2015_1072 · Cited by 71 · see citing works
Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment
Pandey, N., Anastasiadis, P., Carney, C. P., Kanvinde, P. P., Woodworth, G. F., Winkles, J. A., & Kim, A. J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114415 · Cited by 72 · see citing works
Cho, J.-H., Kim, A.-R., Kim, S., Lee, S.-J., Chung, H., & Yoon, M. (2016) · Acta Biomaterialia · doi:10.1016/j.actbio.2016.10.009 · Cited by 71 · see citing works
MicroRNAs: master regulators of drug resistance, stemness, and metastasis
Raza, U., Zhang, J. D., & Şahin, Ö. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1129-2 · Cited by 65 · see citing works
She, X., Yu, Z., Cui, Y., Lei, Q., Wang, Z., Xu, G., Xiang, J., Wu, M., & Li, G. (2014) · Oncology Reports · doi:10.3892/or.2014.3318 · Cited by 65 · see citing works
Liu, Y., Zheng, M., Jiao, M., Yan, C., Xu, S., Du, Q., Morsch, M., Yin, J., & Shi, B. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121036 · Cited by 64 · see citing works
Targeting strategies on miRNA-21 and PDCD4 for glioblastoma
Wang, G., Wang, J. J., Tang, H., & To, S. S. T. (2015) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2015.07.001 · Cited by 63 · see citing works
Exosomal noncoding RNAs: key players in glioblastoma drug resistance
Movahedpour, A., Khatami, S. H., Khorsand, M., Salehi, M., Savardashtaki, A., Mirmajidi, S. H., Negahdari, B., Khanjani, N., Naeli, P., Vakili, O., et al. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04221-2 · Cited by 58 · see citing works
MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel
Liu, R., Liu, X., Zheng, Y., Gu, J., Xiong, S., Jiang, P., Jiang, X., Huang, E., YANG, Y., Ge, D., et al. (2014) · Oncology Letters · doi:10.3892/ol.2014.2500 · Cited by 57 · see citing works
Gaudelot, K., Gibier, J., Pottier, N., Hémon, B., SEUNINGEN, I. V., Glowacki, F., Leroy, X., Cauffiez, C., Gnemmi, V., Aubert, S., et al. (2017) · Tumor Biology · doi:10.1177/1010428317707372 · Cited by 53 · see citing works
Komatsu, S., Ichikawa, D., Kawaguchi, T., Miyamae, M., Okajima, W., Ohashi, T., Imamura, T., Kiuchi, J., Konishi, H., Shiozaki, A., et al. (2016) · Europe PMC (PubMed Central) · Cited by 52 · see citing works
She, X., Yu, Z., Cui, Y., Lei, Q., Wang, Z., Xu, G., Luo, Z., Li, G., & Wu, M. (2014) · Medical Oncology · doi:10.1007/s12032-014-0892-9 · Cited by 52 · see citing works
Noncoding RNAs in Glioblastoma: Emerging Biological Concepts and Potential Therapeutic Implications
Shahzad, U., Krumholtz, S. L., Rutka, J. T., & Das, S. (2021) · Cancers · doi:10.3390/cancers13071555 · Cited by 49 · see citing works
MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer
Faneca, H., Passadouro, M., & de Lima, M. C. P. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s64456 · Cited by 48 · see citing works
miR-25 promotes glioblastoma cell proliferation and invasion by directly targeting NEFL
Peng, G., Yuan, X., Yuan, J., Liu, Q., Dai, M., Shen, C., Jian-rong, M., Liao, Y., & Jiang, W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2516-x · Cited by 45 · see citing works
Poon, W. S., Woo, P. M., Li, Y., Chan, A. Y., Ng, S. P., Loong, H. H.-F., Chan, D. M., & Wong, G. K. C. (2019) · Glioma · doi:10.4103/glioma.glioma_3_19 · Cited by 43 · see citing works
Liu, X., Yidayitula, Y., Zhao, H., Luo, Y., Ma, R., & Xu, M. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-1784-x · Cited by 37 · see citing works
RetractedNoncoding RNAs in Glioblastoma
Zhang, Y., Cruickshanks, N. A., Pahuski, M., Yuan, F., Dutta, A., Schiff, D., Purow, B. W., & Abounader, R. (2017) · Codon Publications eBooks · doi:10.15586/codon.glioblastoma.2017.ch6 · Cited by 38 · see citing works
Genetic and Epigenetic Modulation of Drug Resistance in Cancer: Challenges and Opportunities
Shah, K., & Rawal, R. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200103111539 · Cited by 36 · see citing works
Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer
Akhtarkhavari, T., Bahrami, A. R., & Matin, M. M. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175233 · Cited by 35 · see citing works
MicroRNA-21 with therapeutic potential in autoimmune diseases
Xu, W., Pan, H., Li, J., & Ye, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.773311 · Cited by 35 · see citing works
Engineered smart materials for RNA based molecular therapy to treat Glioblastoma
Singh, R. R., Mondal, I., Janjua, T. I., Popat, A., & Kulshreshtha, R. (2023) · Bioactive Materials · doi:10.1016/j.bioactmat.2023.11.007 · Cited by 35 · see citing works
Mafi, A., Mannani, R., Khalilollah, S., Hedayati, N., Salami, R., Rezaee, M., Dehmordi, R. M., Ghorbanhosseini, S. S., Alimohammadi, M., & Akhavan‐Sigari, R. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01385-x · Cited by 33 · see citing works
Maj, E., Filip‐Psurska, B., Milczarek, M., Psurski, M., Kutner, A., & Wietrzyk, J. (2017) · International Journal of Oncology · doi:10.3892/ijo.2017.4228 · Cited by 32 · see citing works
Melatonin Treatment Improves Renal Fibrosis via miR-4516/SIAH3/PINK1 Axis
Yoon, Y. M., Go, G., Yoon, S., Lim, J. H., Lee, G., Lee, J. H., & Lee, S. H. (2021) · Cells · doi:10.3390/cells10071682 · Cited by 32 · see citing works
Emerging Roles and Potential Applications of Non-Coding RNAs in Glioblastoma
DeOcesano-Pereira, C., Machado, R. A. C., Chudzinski‐Tavassi, A. M., & Sogayar, M. C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072611 · Cited by 30 · see citing works
Exosome and epithelial–mesenchymal transition: A complex secret of cancer progression
Dhar, R., Devi, A., Gorai, S., Jha, S. K., Alexiou, A. T., & Papadakis, M. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17755 · Cited by 29 · see citing works
Managing Pancreatic Adenocarcinoma: A Special Focus in MicroRNA Gene Therapy
Passadouro, M., & Faneca, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050718 · Cited by 29 · see citing works
Chen, H.-W., Lin, R. J., Zhang, Z., Wei, Q., Zhong, Z., Huang, J., & Xu, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10235 · Cited by 27 · see citing works
Cunha, P. P., Costa, P. M., Morais, C. M., Lopes, I. R., Cardoso, A. M., Cardoso, A. L., Mano, M., Jurado, A. S., & de Lima, M. C. P. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx323 · Cited by 27 · see citing works
Self-citationWang, Y.-C., Yang, X., Wei, W., & Xu, X. (2018) · International Journal of Ophthalmology · doi:10.18240/ijo.2018.08.03 · Cited by 27 · see citing works
Recent Trends in Nanotechnology Toward CNS Diseases
Cardoso, A. M., Guedes, J. R., Cardoso, A. L., Morais, C., Cunha, P., Viegas, A. T., Costa, R., Jurado, A., & Pedroso de Lima, M. C. (2016) · International Review of Neurobiology · doi:10.1016/bs.irn.2016.05.002 · Cited by 26 · see citing works
Self-citationMazurek, M., Litak, J., Kamieniak, P., Osuchowska, I., Maciejewski, R., Roliński, J., Grajkowska, W., & Grochowski, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041507 · Cited by 26 · see citing works
Cheng, R. Y. S., Basudhar, D., Ridnour, L. A., Heinecke, J. L., Kesarwala, A. H., Glynn, S. A., Switzer, C., Ambs, S., Miranda, K. M., & Wink, D. A. (2014) · Nitric Oxide · doi:10.1016/j.niox.2014.08.003 · Cited by 24 · see citing works
MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma
Sheng, S., Su, W., Mao, D.-S., Li, C., Hu, X.-Y., Deng, W., Yao, Y., & Ji, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267017 · Cited by 20 · see citing works
Gupta, T., Sahoo, R. K., Singh, H., Katke, S., Chaurasiya, A., & Gupta, U. D. (2023) · AAPS PharmSciTech · doi:10.1208/s12249-023-02555-2 · Cited by 22 · see citing works
Cruz, A. R., Morais, C. M., Cardoso, A. M., Silva, S. G., Vale, M. L. C., Marques, E. F., de Lima, M. C. P., & Jurado, A. S. (2016) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2016.04.014 · Cited by 21 · see citing works
Self-citationRao, V., Kumar, G., Vibhavari, R. J. A., Nandakumar, K., Thorat, N. D., Chamallamudi, M. R., & Kumar, N. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220404180944 · Cited by 20 · see citing works
MiR-124 and MiR-155 as Therapeutic Targets in Microglia-Mediated Inflammation in Multiple Sclerosis
Asl, E. R., Hosseini, S. E., Tahmasebi, F., Bolandi, N., & Barati, S. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01578-6 · Cited by 19 · see citing works
Upregulation of miR-96 promotes radioresistance in glioblastoma cells via targeting PDCD4
Pin, G., Yu, Y., Tian, Z., Lin, Y., Qiu, Y., Yao, W., & Zhang, L. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4498 · Cited by 18 · see citing works
Targeted delivery of small noncoding RNA for glioblastoma
Yoo, J. Y., Yeh, M., Kaur, B., & Lee, T. J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.004 · Cited by 18 · see citing works
Comparison of microRNA expression levels between initial and recurrent glioblastoma specimens
Ilhan‐Mutlu, A., Wöehrer, A., Berghoff, A. S., Widhalm, G., Marosi, C., Wagner, L., & Preusser, M. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1078-6 · Cited by 16 · see citing works
Cardoso, A. M., Morais, C. M., Pena, F. M. E., Marante, T., Cunha, P. P., Jurado, A. S., & de Lima, M. C. P. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab011 · Cited by 15 · see citing works
Self-citationEffects of Micrornas and Long Non-Coding RNAs on Chemotherapy Response in Glioma
Ahmadpour, S., Taghavi, T., Sheida, A., Zadeh, S. S. T., Hamblin, M. R., & Mirzaei, H. (2022) · Epigenomics · doi:10.2217/epi-2021-0439 · Cited by 15 · see citing works
Zadran, S., Remacle, F., & Levine, R. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108171 · Cited by 15 · see citing works
Bao, X., Wang, M., Zhang, Y.-P., & Zhang, Y.-J. (2014) · BioMed Research International · doi:10.1155/2014/218578 · Cited by 13 · see citing works
Morais, C. M., Cardoso, A. M., Cunha, P. P., Aguiar, L., Vale, N., Lage, E. V., Pinheiro, M., Nunes, C., Gomes, P. A. C., Reis, S., et al. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.10.002 · Cited by 13 · see citing works
Self-citationRivalin, R., Lépinoux-Chambaud, C., Eyer, J., & Savagner, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098473 · Cited by 12 · see citing works
St‐Cœur, P., Touaibia, M., Čuperlović‐Culf, M., & Morin, P. (2013) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2013.04.003 · Cited by 11 · see citing works
Morais, C. M., Cardoso, A. M., Aguiar, L., Vale, N., Nóbrega, C., Zuzarte, M., Gomes, P. A. C., de Lima, M. C. P., & Jurado, A. S. (2020) · Pharmaceutical Research · doi:10.1007/s11095-020-02904-x · Cited by 8 · see citing works
Self-citationResearch progress on ncRNAs regulation of mitochondrial dynamics in diabetes
Wu, Y., Lan, H., Zhang, D., Hu, Z., Zhang, J., Li, Z., Xia, P., Tang, X., Cai, X., & Yu, P. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30878 · Cited by 7 · see citing works
Mechanisms of Chemoresistance in High-Grade Gliomas
SohrabiAsl, M., Iranmehr, A., & Hanaei, S. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_185 · Cited by 4 · see citing works
MicroRNAs in the Molecular Pathology of Gliomas
Šáňa, J., Bešše, A., & Slabý, O. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1431-5_4 · Cited by 1 · see citing works
Anti-Angiogenesis, Gene Therapy, and Immunotherapy in Malignant Gliomas
Province, P., Shaefer, A. B., McCullough, B., & Fathallah‐Shaykh, H. M. (2014) · InTech eBooks · doi:10.5772/58320
Exploring New Strategies to Overcome Resistance in Glioblastoma Multiforme: A Dissertation
Ellis, Y. P. (2015) · eScholarship@UMassChan · doi:10.13028/m2jc7j
PREDICTIVE RELAPSE MODEL IN PATIENTS WITH LUMINAL HER2-NEGATIVE BREAST CANCER
Торосян, М. Х., Shevchenko, T. V., Родионов, В. В., Yu, S. Y. G. S., Veryaskina, Y. A., Кометова, В. В., & Гакифович, Ш. М. (2020) · Ulyanovsk Medico-biological Journal · doi:10.34014/2227-1848-2020-4-61-73
Parsyan, A. E., Meyerowitz, J., & Weiss, W. A. (2014) · Springer eBooks · doi:10.1007/978-94-017-9078-9_24
Oncogenic miRNAs as Therapeutic Targets: Opportunities and Challenges
Kotthapalli, P., & Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-5989-3_4
Innovative approaches with molecularly imprinted polymers for targeting brain cancer
Rajkumar, M., Presley, S. I. D., Kirubakaran, D., & Prajapati, B. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41778-8.00009-7
- Authors
- Costa, P. M., Cardoso, A. L., Nóbrega, C., Pereira de Almeida, L. F., Bruce, J. N., Canoll, P., & Pedroso de Lima, M. C.
- Affiliations
- Centro de Neurociências e Biologia Celular (PT)
- Columbia University (US)
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-11-30
- Volume
- 22
- Issue
- 5
- Pages
- 904-918
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- PMC
- PMC3561912
- OpenAlex
- W2141130224
- Cited by
- 80
- References
- 69
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2023: 5 · 2022: 7 · 2021: 5 · 2020: 9 · 2019: 4 · 2018: 6 · 2017: 7 · 2016: 7 · 2015: 8 · 2014: 12 · 2013: 6
- FWCI
- 2.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Human Molecular Genetics (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Fundação para a Ciência e a Tecnologia (SFRH/BD/45902/2008)
- National Institute of Neurological Disorders and Stroke (R01NS073610, R01NS066955)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Genetics › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- miR-21, glioblastoma, sunitinib, anti-angiogenic therapy, microRNA-128, PTEN, PDCD4, caspase-3/7 activation, p53, temozolomide, tumor cell proliferation, gene therapy
- MeSH terms
- Sunitinib, Animals, Brain Neoplasms, Glioblastoma, Humans, Indoles, Pyrroles, Signal Transduction, Down-Regulation, Up-Regulation, Gene Expression Regulation, Neoplastic, RNA-Binding Proteins, Angiogenesis Inhibitors, MicroRNAs, Cell Line, Tumor, Cell Proliferation, Apoptosis Regulatory Proteins, PTEN Phosphohydrolase, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
